SEARCH

SEARCH BY CITATION

References

  • 1
    Soriano V, Barreiro P, Sherman KE. The changing epidemiology of liver disease in HIV patients. AIDS Rev 2013;15:2531.
  • 2
    Stall R, Duran L, Wisniewski SR, Friedman MS, Marshal MP, McFarland W, et al. Running in place: implications of HIV incidence estimates among urban men who have sex with men in the United States and other industrialized countries. AIDS Behav 2009;13:615629.
  • 3
    Hall HI, Frazier EL, Rhodes P, Holtgrave DR, Furlow-Parmley C, Tang T, et al. Continuum of HIV care: differences in care and treatment by sex and race/ethnicity in the United States. J Int AIDS Soc 2012;15:8686.
  • 4
    Soriano V, Sherman KE, Rockstroh J, Dieterich D, Back D, Sulkowski M, Peters M. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. AIDS 2011;25:21972208.
  • 5
    Crum-Cianflone NF, Curry J, Drobeniuc J, Weintrob A, Landrum M, Ganesan A, et al. Hepatitis E virus infection in HIV-infected persons. Emerg Infect Dis 2012;18:502506.
  • 6
    Kenfak-Foguena A, Schoni-Affolter F, Burgisser P, Witteck A, Darling KE, Kovari H, et al. Hepatitis E Virus seroprevalence and chronic infections in patients with HIV, Switzerland. Emerg Infect Dis 2011;17:10741078.
  • 7
    Sellier P, Mazeron MC, Tesse S, Badsi E, Evans J, Magnier JD, et al. Hepatitis E virus infection in HIV-infected patients with elevated serum transaminases levels. Virol J 2011;8:171.
  • 8
    Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2010;65:543547.
  • 9
    Maida I, Nunez M, Rios MJ, Martin-Carbonero L, Sotgiu G, Toro C, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006;42:177182.
  • 10
    Vispo E, Cevik M, Rockstroh JK, Barreiro P, Nelson M, Scourfield A, et al. Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients. Clin Infect Dis 2013;56:11171122.
  • 11
    Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011;141:16651672.e1-9.
  • 12
    Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308:387402.
  • 13
    Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, et al. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med 2012;9:e1001194.
  • 14
    Limketkai BN, Mehta SH, Sutcliffe CG, Higgins YM, Torbenson MS, Brinkley SC, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012;308:370378.
  • 15
    McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, et al. The HBV drug entecavir—effects on HIV-1 replication and resistance. N Engl J Med 2007;356:26142621.
  • 16
    Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis 2004;38:e7980.
  • 17
    Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE. The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Aliment Pharmacol Ther 2011;33:12341244.
  • 18
    Mikl J, Sulkowski MS, Benhamou Y, Dieterich D, Pol S, Rockstroh J, et al. Hepatic profile analyses of tipranavir in phase II and III clinical trials. BMC Infect Dis 2009;9:203.
  • 19
    Schiano TD, Uriel A, Dieterich DT, Fiel MI. The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV. Virchows Arch 2011;458:231235.
  • 20
    Vispo E, Moreno A, Maida I, Barreiro P, Cuevas A, Albertos S, Soriano V. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010;24:11711176.
  • 21
    Macias J, Berenguer J, Japon MA, Giron JA, Rivero A, Lopez-Cortes LF, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009;50:10561063.
  • 22
    Lin W, Weinberg EM, Chung RT. Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis 2013;207(Suppl 1):S13S18.
  • 23
    Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim KA, et al. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 2008;134:803811.
  • 24
    Lin W, Tsai WL, Shao RX, Wu G, Peng LF, Barlow LL, et al. Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology 2010;138:25092518, 2518.e1.
  • 25
    Lin W, Wu G, Li S, Weinberg EM, Kumthip K, Peng LF, et al. HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem 2011;286:26652674.
  • 26
    Jang JY, Shao RX, Lin W, Weinberg E, Chung WJ, Tsai WL, et al. HIV infection increases HCV-induced hepatocyte apoptosis. J Hepatol 2011;54:612620.
  • 27
    Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008;135:226233.
  • 28
    Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007;13:13241332.
  • 29
    Puoti M, Rossotti R, Garlaschelli A, Bruno R. Hepatocellular carcinoma in HIV hepatitis C virus. Curr Opin HIV AIDS 2011;6:534538.
  • 30
    Brau N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007;47:527537.
  • 31
    Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalite 2005 study. J Hepatol 2009;50:736745.
  • 32
    Shiels MS, Pfeiffer RM, Hall HI, Li J, Goedert JJ, Morton LM, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA 2011;305:14501459.
  • 33
    Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med 2010;153:452460.
  • 34
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:10201022.
  • 35
    Kirk GD, Mehta SH, Astemborski J, Galai N, Washington J, Higgins Y, et al. HIV, Age, and the severity of hepatitis C virus-related liver Disease: a cohort study. Ann Intern Med 2013;158:658666.
  • 36
    Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417422.
  • 37
    Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58:1207; quiz, CE201-CE204.
  • 38
    Tuma P, Jarrin I, Del Amo J, Vispo E, Medrano J, Martin-Carbonero L, et al. Survival of HIV-infected patients with compensated liver cirrhosis. AIDS 2010;24:745753.
  • 39
    Murillas J, Rimola A, Laguno M, de Lazzari E, Rascon J, Aguero F, et al. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. Liver Transpl 2009;15:11331141.
  • 40
    Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, M, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant 2010;10:12681275.
  • 41
    Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012;18:716726.
  • 42
    Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat 2007;14:239248.
  • 43
    Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009;50:407413.
  • 44
    Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013;169:8696.
  • 45
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:24052416.
  • 46
    Sherman KE. Response-guided telaprevir combination treatment for hepatitis C virus infection (vol 365, pg 1014, 2011). N Engl J Med 2011;365:1551.
  • 47
    Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:11951206.
  • 48
    Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA. Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin Infect Dis 2012;54:979983.
  • 49
    Dieterich D, Rockstroh J, Orkin C, Gutierrez F, Klein M, Reynes J, et al.Simeprevir with pegylated interferon/ribavirin in patients co-infected with chronic hepatitis C virus and HIV-1: week-24 interim analysis of the TMC435-C212 study (Abstract 154LB). Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta, GA.
  • 50
    Dieterich D, Soriano V, Nelson M, Rockstroh J, Arasteh K, Bhagani S, et al.STARTVerso 4: high rates of early virologic response in hepatitis C virus genotype 1/HIV co-infected patients treated with faldaprevir + pegylated interferon and ribavirin (Abstract 40LB). Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta, GA.
  • 51
    Bifano M, Hwang C, Oosterhuis B, Hartstra J, Tiessen R, Velinova-Donga M, et al.Assessment of HIV ARV drug interactions with the HCV NS5A replication complex inhibitor BMS-790052 demonstrates a pharmacokinetic profile which supports co-administration with tenofovir disoproxil fumarate, efavirenz, and atazanavir/ritonavir (Abstract 618). In: 19th Conference on Retroviruses and Opportunistic Infections (CROI), March 5-8, 2012, Seattle, WA.
  • 52
    Rodriguez-Torres M, Gonzales M, Rodriguez J, Rossi S, Shen G, Mathias A, et al.HIV/HCV co-infected and HCV monoinfected patients have similar early hepatitis C viral kinetics with the potent HCV nucleotide polymerase inhibitor sofosbuvir. In: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9-12, 2012, San Francisco, CA.
  • 53
    Khalsa JH, Treisman G, McCance-Katz E, Tedaldi E. Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse. Subst Abus 2008;29:516.
  • 54
    Ho SB, Groessl E, Dollarhide A, Robinson S, Kravetz D, Dieperink E. Management of chronic hepatitis C in veterans: the potential of integrated care models. Am J Gastroenterol 2008;103:18101823.
    Direct Link:
  • 55
    Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, Fischer B, Tyndall MW. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009;16:352358.
  • 56
    Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006;20:23612369.
  • 57
    Myles A, Mugford GJ, Zhao J, Krahn M, Wang PP. Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can J Gastroenterol 2011;25:135139.
  • 58
    Marco A, Esteban JI, Solé C, da Silva A, Ortiz J, Roget M, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol 2013;59:4551.
  • 59
    Page K, Osburn W, Evans J, Hahn JA, Lum P, Asher A, et al. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis 2013;56:405413.
  • 60
    Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012;12:408414.
  • 61
    Lucas GM, Chaudhry A, Hsu J, Woodson T, Lau B, Olsen Y, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Ann Intern Med 2010;152:704711.
  • 62
    Treisman G, Angelino A. Interrelation between psychiatric disorders and the prevention and treatment of HIV infection. Clin Infect Dis 2007;45(Suppl 4):S313S317.